GOSS — Gossamer Bio, Inc.

Is GOSS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of August 19, 2026

Gossamer Bio, Inc. (GOSS) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $0.14. The rating moved from Oversold to Strong Oversold on August 15, 2026.

See all oversold Healthcare stocks →

AI analysis

Gossamer Bio, Inc. (GOSS) is trading at a deeply discounted level where equity value is primarily driven by binary clinical and financing outcomes. Provided data lacks recent filings and detailed cash/runway figures, increasing uncertainty. The firm appears exposed to dilution risk and clinical/regulatory binary events; absent clear near-term positive catalysts or partnerships, downside is the higher-probability path. Broader sector tailwinds for biologics and CDMO demand exist but are unlikely to materially de-risk the company without late-stage, partner-backed assets. Social sentiment and granular financial disclosures were not available in the dataset, which constrains visibility on market perception and short-term funding prospects.

Key factors

  • Very low share price and likely limited market capitalization implies high financing pressure and potential near-term dilution
  • Clinical-stage biotech profile with no material commercial revenue; value depends on binary clinical/regulatory outcomes
  • Broad sector backdrop favors biologics and CDMO demand, but Gossamer Bio may not directly benefit without late-stage assets or partnerships
  • Absence of recent EDGAR/filing detail in provided data increases uncertainty about cash runway and milestone timelines
  • Macro market tone is mildly risk-on which can temporarily support speculative biotech flows, but sustainable recovery needs concrete pipeline catalysts
  • Low liquidity and thin trading typical for deeply discounted biotech names increases volatility and downside on negative news

Risks

  • Severe dilution from equity raises to extend cash runway, further depressing share value
  • Clinical trial failures or negative readouts for pipeline programs leading to permanent value impairment
  • Regulatory setbacks or extended review timelines that push out value-inflection events
  • Adverse partner or licensing outcomes (failed deals, discontinued collaborations)
  • Market illiquidity causing exaggerated price moves on small volumes or block sales
  • Competitive advances from larger biotech/pharma that make Gossamer’s programs less commercially viable

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for GOSS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.